Mirae Asset Venture Investments

Mirae Asset Venture Investments is the venture capital arm of Mirae Asset Financial Group, a major South Korean financial services firm. The fund deploys $5M to $25M checks at Series B, Series C, and growth stages, with a documented preference for scaling Indian technology platforms in addition to its Korean and pan-Asian deal flow. Healthcare exposure is concentrated in digital health rather than therapeutics or biotech.

The firm’s posture is that of a financially driven growth investor with strategic optionality from the broader Mirae Asset franchise. The natural fit is with category-leading digital health platforms in India, Southeast Asia, or Korea that are raising priced Series B or C rounds with clear unit economics, strong retention metrics, and a credible path to either profitability or a public listing event. Founders below Series B, founders without strong revenue traction, or founders pitching primarily on AI architectural moats are not the right fit. Mirae Asset is not particularly AI-thematic; the lens is commercial.

Geographically, the advantage is two-sided. For Indian growth-stage founders, the firm offers an additional pool of pan-Asian capital and connectivity to Korean and broader Asian public market investors that can matter for IPO syndication. For Korean-headquartered founders, the strategic value is the parent group’s distribution and capital markets relationships. For founders headquartered outside Asia, the strategic logic is thin.

The right entry path is via an investment banker leading the round, an existing late-stage co-investor, or a senior board member with Mumbai or Seoul growth-stage relationships. Decks should lead with revenue, gross margin, retention cohorts, and a clear use of proceeds tied to a near-term liquidity path. The pitch should be calibrated to financial returns rather than thematic alignment; the firm’s lens is fundamentals.

Caveats. As a corporate-affiliated growth investor, Mirae Asset can move at the pace of large institutional diligence; budget timeline accordingly. The healthcare-specific track record outside the broader Mirae Asset balance sheet is not as visible as that of pure-play healthcare growth funds; for deeply specialized clinical or therapeutic assets, dedicated healthcare growth investors are likely a better lead. Confirm the firm’s healthcare governance philosophy and follow-on appetite via reference calls with existing growth-stage founders. For an Indian or Korean digital health category leader at scale, Mirae Asset is a credible name on a Series B or C cap table; for early-stage founders, this is the wrong door.